CMS: Makers of selected drugs agree to participate in Medicare price negotiation
The companies that make the first 10 Medicare Part D drugs selected to participate in the Medicare Drug Price Negotiation Program have agreed to participate in the program’s price negotiations, the Centers for Medicare & Medicaid Services announced. CMS in August selected 10 high-cost drugs for the first negotiation cycle, which will run until next August for prices effective in 2026. It plans to host public meetings on each of the drugs between Oct. 30 and Nov. 15, and make initial price offers for the drugs by Feb. 1.
Related News Articles
Headline
The Centers for Medicare & Medicaid Services June 28 released a proposed rule on mitigating the impact of significant, anomalous and highly suspect (SAHS)…
Headline
The Department of Health and Human Services June 26 announced beneficiary coinsurance reductions for 64 prescription drugs available through Medicare Part B.…
Perspective
For too long and for too many patients, the process of obtaining prior authorization for a medical procedure or medicine has been a tangled web, as people are…
Headline
The AHA June 14 sent a letter to the Senate Finance Committee, responding to questions included in a white paper the committee wrote on chronic care through…
Headline
The Centers for Medicare & Medicaid Services estimates national health spending grew 7.5% in 2023, reflecting increases in insurance growth, the agency…
Headline
The Medicare Payment Advisory Commission June 13 released its June report to Congress. As urged by the AHA, the commission did not recommend a payment…